Epiminder Announces 5-Year Milestone of Long-Term Continuous EEG Monitoring Implant
The longest continuous EEG monitoring device implanted in human passes the 5-year mark.
Melbourne, Australia – November 24, 2024 – Epi-Minder Pty Ltd, a medical technology company focused on the development and commercialization of a sub-scalp Continuous Electroencephalogram (EEG) Monitoring device, Minder®, announced a significant milestone in its research and development program. As part of the UMPIRE study (s U b-scalp M onitoring of e P ileptic se I zu RE s), a prospective, clinical trial in Australia, the Minder device has recorded continuous EEG for five years in a study participant. To date, this is the longest continuous EEG recording ever captured in man. This is an important milestone in the evolving paradigm of EEG monitoring for drug resistant epilepsy patients and could open a path to seizure freedom.
Rohan Hoare, Chief Executive Officer of Epiminder, stated: “Our investment in developing the Minder device is proving to clinicians in the field of neurology that long term, continuous EEG monitoring is becoming a reality. Patients with drug resistant epilepsy manage a very challenging path to seizure freedom and this is often the result of not having objective long term seizure data for them and their treating neurologist to make the best informed clinical decisions. The Minder continuous EEG monitor holds the promise of delivering actionable insights to clinicians and patients to help them improve seizure control and, for some, achieve seizure freedom.”
About epilepsy
Epilepsy affects 80 million people globally with current medications only effective in two in three cases. More than 250,000 Australians and 3.4 million Americans are currently living with epilepsy, the most common brain disorder worldwide that can affect people at any age. Refractory epilepsy affects 30-40% of these patients, who cannot be adequately managed by drug therapy to remain seizure free.
About Minder
Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.
Minder’s long-term monitoring of patients outside of a controlled clinical environment is expected to lead to more effective treatment of underlying conditions, including determining the effectiveness of drug therapies and other potential interventions. Currently the device is for investigational use only.
About Epi-Minder Pty Ltd
Epiminder is a medical device company focused on the development of sub-scalp, Continuous EEG Monitoring system for people who suffer from epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has subsidiaries operating in the United States.